Your browser doesn't support javascript.
loading
Improving the pharmacokinetic and CYP inhibition profiles of azaxanthene-based glucocorticoid receptor modulators-identification of (S)-5-(2-(9-fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341).
Yang, Michael G; Dhar, T G Murali; Xiao, Zili; Xiao, Hai-Yun; Duan, James J-W; Jiang, Bin; Galella, Michael A; Cunningham, Mark; Wang, Jinhong; Habte, Sium; Shuster, David; McIntyre, Kim W; Carman, Julie; Holloway, Deborah A; Somerville, John E; Nadler, Steven G; Salter-Cid, Luisa; Barrish, Joel C; Weinstein, David S.
Affiliation
  • Yang MG; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Dhar TG; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Xiao Z; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Xiao HY; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Duan JJ; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Jiang B; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Galella MA; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Cunningham M; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Wang J; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Habte S; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Shuster D; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • McIntyre KW; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Carman J; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Holloway DA; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Somerville JE; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Nadler SG; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Salter-Cid L; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Barrish JC; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Weinstein DS; Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
J Med Chem ; 58(10): 4278-90, 2015 May 28.
Article in En | MEDLINE | ID: mdl-25905990

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Experimental / Thiadiazoles / Receptors, Glucocorticoid / Cytochrome P-450 Enzyme Inhibitors / Heterocyclic Compounds, 3-Ring Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Experimental / Thiadiazoles / Receptors, Glucocorticoid / Cytochrome P-450 Enzyme Inhibitors / Heterocyclic Compounds, 3-Ring Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States